1/ This is either ignorant or dishonest about Trump's trade policy on drug pricing. It's the other way around - Trump's policy is to *increase* the prices paid for drugs outside the US.
2/ Here's Trump's policy on drug pricing in his own words, objecting to "unreasonably low prices" outside the US - from the House of Lords library briefing on "the NHS and future trade deals", 4 July 2019 
3/ Some have objected to Corbyn saying that Trump seeks "full market access" for medical products. But this phrase is found in the Trump administration's own public document setting out its objectives in the US/UK talks.
4/ Again: this falls short of the claim that "the NHS is for sale" in the trade talks with Trump. But we do know:
a) patents/NHS drug pricing is under discussion (although we can't be certain what final FTA would say on this)
b) Trump's objective is NHS paying *more*, not less
a) patents/NHS drug pricing is under discussion (although we can't be certain what final FTA would say on this)
b) Trump's objective is NHS paying *more*, not less
5/ Interesting point - Trump doesn't like UK staying part of Unified Patent Court. Would mean part of the court leaving London. Not explicitly an EU court but linked to EU law on the unified patent. Not clear what happens after Brexit on this issue.
6/ Looks like Guido deleted his inaccurate tweet about Trump's trade policy and NHS drug pricing. Here's the screenshot.
7/
